Know Cancer

forgot password

A Phase II Multi-Center Study of Bevacizumab in Combination With Ixabepilone in Subjects With Advanced Renal Cell Carcinoma

Phase 2
18 Years
Open (Enrolling)
Renal Cell Carcinoma

Thank you

Trial Information

A Phase II Multi-Center Study of Bevacizumab in Combination With Ixabepilone in Subjects With Advanced Renal Cell Carcinoma


- Substantial preclinical antitumor synergy supports the exploration of the combination
of antiangiogenic compounds (including sunitinib and bevacizumab) plus ixabepilone. In
Vivo, synergistic activity between ixabepilone and bevacizumab has been demonstrated
using the 151-B human renal carcinoma xenograft model and this synergy compares
favorably with other antiangiogenic inhibitors (i.e. sunitinib).

- Combination therapies of bevacizumab with chemotherapy demonstrated improved benefit
compared with single-agent cytotoxics in multiple animal models and in humans.

- Clinical activity of both compounds used as single agents has been demonstrated in a
broad spectrum of solid tumors. Bevacizumab and ixabepilone, when used as a single
agent, have demonstrated substantial activity in renal cell carcinoma. Ixabepilone is
currently being evaluated in a Phase II study (CCR/NCI, Tito Fojo MD, PhD, PI) in stage
IV renal carcinoma, with encouraging preliminary activity.

- Phase II studies with bevacizumab and ixabepilone suggest the absence of overlapping

- Development of a well-tolerated and active bevacizumab/ixabepilone combination has the
potential to further improve the treatment of metastatic renal cell carcinoma (mRCC),
and could represent a second-line option after sunitinib or sorafenib are no longer of
benefit or are intolerable.

Primary Objective:

- Determine the objective response rate of the combination of ixabepilone and bevacizumab
in patients with relapsed or refractory mRCC.

- Determine progression-free survival.

- Characterize the toxicity of the combination of ixabepilone and bevacizumab in patients
with mRCC.

- Determine changes in biomarkers and evaluate correlation with clinical outcomes.


- Pathologic confirmation of renal cell carcinoma (clear cell histology) by the
Laboratory of Pathology, NCI or the Medical University of South Carolina..

- Presence of metastatic renal carcinoma, after progression or intolerance to VEGFR
inhibitors (sunitinib and/or sorafenib).

- Adequate organ and bone marrow function.


- Multi-center, open labeled phase II study

- Following a Simon two-stage optimal design, a maximum of 58 patients with metastatic
RCC will be accrued over a period of 24 months.

- Ixabepilone will be administered daily as a one hour infusion on five successive days
(daily x 5), every three weeks (one cycle equals 3 weeks or 21 days). The starting dose
will be a daily dose of 6 mg/m(2)/day, for a total per cycle dose of 30 mg/m(2).

- In addition, 15 mg/kg bevacizumab will be administered intravenously on day 1 of each
cycle. The first infusion of bevacizumab will be 90 minutes in duration, the second 60
minutes in duration, and in all subsequent cycles bevacizumab will be infused over 30
minutes if prior infusions are well tolerated.

Inclusion Criteria


Subjects meeting all of the following criteria will be considered for enrollment into the

1. Pathologic confirmation of metastatic or unsectable renal cell carcinoma with
predominant clear cell histology (greater than 70%) by the Laboratory of Pathology,
NCI or the Medical University of South Carolina..

2. Progression on or after stopping treatment with an agent approved by the FDA for the
treatment of RCC. Patients must have received at least on FDA approved agent
(sunitinib, sorafenib, pazopanib, temsirolimus or everolimus- Sutent, Nexavar,
Votrient, Torisel or Affinitor). Prior IL-2, interferon treatment is allowed, but not
mandatory. Patients must be off of prior therapy for at least 4 weeks prior to entry.

3. Eighteen years of age or older.

4. ECOG performance status less than or equal to 2.

5. Resolution of any toxic effects of prior therapy (except alopecia) to NCI CTCAE v.3.0
through 12/31/10 and version 4.0 beginning 1/1/11 grade less than or equal to 1 and
to baseline laboratory values as defined in inclusion criterion # 6.

6. Adequate organ and bone marrow function as evidenced by:

- hemoglobin greater than or equal to 9.0 g/dL

- absolute neutrophil count greater than or equal to 1.5 x 10(9)/L

- platelet count greater than or equal to 100 x 10(9)/L

- creatinine less than or equal to 1.5 times the ULN, OR measured creatinine
clearance greater than or equal to 40 ml/min

- urine proteinuria less than 20mg/dL on randon protein creatinine ratio urine
samples or a 24-hour urine protein less than 500 mg. NOTE: If on a random
protein creatinine ratio the urine protein is greater that or equal to 20mg/dL,
then obtain a 24 hour urine collection to accurately demonstrate that the 24
hour total is less than 500 mg/24 hours.

- AST/SGOT and ALT/SGPT less than or equal to 2.5 times the ULN (or less than or
equal to 5 times the ULN if liver function abnormalities due to underlying

- total bilirubin less than or equal to 1.5 times the ULN

7. Subjects must be postmenopausal, surgically sterile, or using effective
contraception. All female subjects of childbearing potential must have a negative
pregnancy test (serum or urine) within 7 days prior to enrollment. Effective
contraception includes hormonal or barrier methods.

8. No other invasive malignancies within the past two years (with the exception of
nonmelanoma skin cancers, non-invasive bladder cancer, stage I endometrial cancer or
cervical cancer).

9. Subjects must agree to sign and date an Institutional Review Board (IRB)-approved
subject informed consent form.

10. Subjects must be willing and able to comply with scheduled visits, treatment plans,
laboratory tests, and other study procedures.

11. Patients must have measurable disease either by conventional imaging or clinical


Subjects presenting with any of the following will not be included in the study:

1. Invasive procedures defined as follows:

- Major surgical procedure, open biopsy or significant traumatic injury within 6
weeks prior to Day 1 therapy

- Anticipation of need for major surgical procedures during the course of the

- Minor surgery, such as port-a-cath placement, and dental procedures, within 2

- (There will be no delay for percutaneous core biopsies or PICC/IJ line

2. Cumulative radiation therapy to greater than 25% of the total bone marrow.

3. History of uncontrolled or labile hypertension, defined as blood pressure greater
than 160/90 mm Hg (NCI CTCAE v.3.0 through 12/31/10 and version 4.0 beginning 1/1/11
grade greater than or equal to 2), on at least 2 repeated determinations on separate
days within 15 days prior to study enrollment.

4. Any of the following within 6 months prior to study enrollment: myocardial
infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft,
NYHA class III or IV congestive heart failure; cerebrovascular accident or transient
ischemic attack, grade greater than or equal to 2 peripheral neuropathy, peptic ulcer
disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease,
diverticulitis, or other thromboembolic event.

5. Symptomatic spinal cord compression.

6. Evidence of clinically significant bleeding diathesis or underlying coagulopathy.

7. Antiretroviral therapy for HIV disease.

8. Pregnant (positive pregnancy test) or nursing women. Both fertile men and women must
agree to use adequate contraceptive measures during study therapy and for at least 6
months after the completion of bevacizumab therapy.

9. Other severe acute or chronic medical or psychiatric condition, or significant
laboratory abnormality requiring further investigation that may cause undue risk for
the subject's safety, 18 inhibit protocol participation, or interfere with
interpretation of study results, and in the judgment of the investigator would make
the subject inappropriate for entry into this study.

10. Prior therapy with bevacizumab

11. Prior therapy with ixabepilone.

12. Patients on anticoagulant therapy will be evaluated on a case by case basis for

13. Serious or non-healing wound, ulcer or bone fracture

14. History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess
within 6 months prior to day 1

15. Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or
recent peripheral arterial thrombosis) within 6 months prior to Day 1

16. Known CNS disease except for treated brain metastasis.

-Treated brain metastases are defined as having no ongoing requirement for steroids
and no evidence of progression or hemorrhage after treatment for at least 3 months,
as ascertained by clinical examination and brain imaging (MRI or CT). (Stable dose of
anticonvulsants are allowed). Treatment for brain metastases may include whole brain
radiotherapy (WBRT), radiosurgery (RS; Gamma Knife, LINAC, or equivalent) or a
combination as deemed appropriate by the treating physician. Patients with CNS
metastases treated by neurosurgical resection or brain biopsy performed within 3
months prior to Day 1 will be excluded.

17. Patients with known hypersensitivity of Chinese hamster ovary cell products or other
recombinant human antibodies

18. Patients receiving CYP3A4 inhibitors in section 3.6 that cannot be discontinued.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Response rate per RECIST.

Principal Investigator

Antonio T Fojo, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

National Cancer Institute (NCI)


United States: Federal Government

Study ID:




Start Date:

December 2008

Completion Date:

November 2014

Related Keywords:

  • Renal Cell Carcinoma
  • Renal Cell Carcinoma
  • Bevacizumab
  • Ixabepilone
  • Phase II
  • Carcinoma
  • Carcinoma, Renal Cell



National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland  20892
Medical University of South Carolina Charleston, South Carolina  29425-0721